Oculis Sets Year-End 2026 Data Readout for Licaminlimab as Privosegtor Expands Toward Acute MS Relapses
Market Chameleon (Wed, 4-Nov 8:34 AM)
Oculis Highlights Privosegtor’s Phase 2 Optic Neuritis Signals as PIONEER Registrational Program Moves Forward
Market Chameleon (Fri, 30-Oct 11:07 AM)
Oculis finishes PREDICT-1 randomization with 176 patients, putting a genotype-guided dry eye readout on the 2026 calendar
Market Chameleon (Tue, 20-Oct 11:50 AM)
